August 18, 2021Open Access

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

Pembrolizumab treatment led to a significant improvement in disease-free survival as compared with placebo after surgery among patients with kidney cancer who were at high risk for recurrence. (Funded by Merck Sharp and Dohme, a subsidiary of Merck; KEYNOTE-564 ClinicalTrials.gov number, NCT03142334.).

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Toni K. Choueiri

Piotr Tomczak

Se Hoon Park

Journals

ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)

New England Journal of Medicine

Actions

Institutions

University of Michigan

University College London

Dana-Farber Cancer Institute

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider